Bevacizumab (Avastin) gets another life-extension
FDA postponed its decision on whether to withdraw Avastin (Bevacizumab) approval for breast cancer treatment to December 17.
Some breast cancer patients and advocacy groups were opposed to the Advisory council recommendation to withdraw the approval of bevacizumab in breast cancer treatment. I am adapting a feature news from SciGuru.com for details: "The news on bevacizumab is gaining traction again. Recently US Food and Drug Administration's (FDA) Oncology Advisory Panel recommended to withdraw approval for bevacizumab in the treatment of breast cancer. It may be noted that, in 2008, FDA went against the recommendation of its advisory panel and approved the drug for breast cancer treatment....Click here for details